The FDA outlined progress and a policy roadmap aimed at phasing out animal testing requirements where nonclinical alternatives can be equivalent or better. The agency’s work includes establishing a permanent pathway for qualifying new drug development tools and recognizing cell-based assays, organ-chips, and computer models as legitimate nonclinical tests. The piece also stresses a key remaining scientific barrier: ensuring the authenticity and traceability of biological materials used in new approach methodologies. As NAM datasets feed shared modeling pipelines, a single flawed input could propagate errors beyond the originating lab.
Get the Daily Brief